Saturday, Apr 27 2024 | Time 02:28 Hrs(IST)
image
Business EconomyPosted at: Nov 5 2019 11:55AM


Biocon's Biologics drug products facility receives EIR from US FDA

Bengaluru, Nov 5 (UNI) Biocon Ltd, an innovation-led global biopharmaceuticals company, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Biologics Drug Product facility in Bengaluru.
Biocon had undergone a surveillance cGMP inspection of this Drug Product facility in Bengaluru from August 22 to 30, 2019, according to a Biocon statement here on Tuesday.
Dr Christiane Hamacher, CEO, Biocon Biologics said, ''We are pleased to receive the EIR from the US FDA for our large Biologics Drug Product facility in Bengaluru, which is a strong building block for our US Dollar One billion revenue target. We have US FDA approvals for bPegfilgrastim and bTrastuzumab, and have been making a difference to cancer patients with bPegfilgrastim".
The US FDA in October had also approved Biocon's new Drug Product (DP) filling line for biosimilar Trastuzumab 150 mg vials at the Biologics facility in Bengaluru.
"We are targeting to serve the needs of over 2.5 million patients in FY20. We aspire to serve nearly five million patients and cross revenues of USD one billion by FY22, driven by the near term commercialisation of Trastuzumab and Insulin Glargine in the US, continual growth in existing developed and emerging markets and launch of Insulin Aspart and Bevacizumab in various global markets," he added.
Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, several with Sandoz, and is developing many independently. The company's therapeutic basket includes molecules from diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases.
To address volume growth on account of increased penetration of its products in developed and emerging markets and also to support new biosimilar pipeline development and launches, Biocon Biologics is investing in expanding its manufacturing capacities, in line with its approach of modular expansion.
The company has also been undertaking strategic partnerships and acquisitions to rapidly expand its biosimilars portfolio and increase the addressable market opportunity.
UNI MSP RJ 1153
Please log in to get detailed story.
Tags: #Biocon's Biologics drug products facility receives EIR from US FDA
More News
Sensex nosedives 609 28 pts

Sensex nosedives 609 28 pts

26 Apr 2024 | 5:26 PM

Mumbai, April 26 (UNI) Snapping a winning streak of last five sessions, the BSE Sensex on Friday, the last session of the week, tanked 609.28 pts to settle at 73730.16 amid mixed global cues.

see more..
Maruti Suzuki net profit surges 48 pc to Rs 3,878 crore in Q4

Maruti Suzuki net profit surges 48 pc to Rs 3,878 crore in Q4

26 Apr 2024 | 5:00 PM

New Delhi, April 26 (UNI) On the back of solid volume growth, the country's largest carmaker Maruti Suzuki on Friday reported 47.80% jump in standalone net profit at Rs 3,877.8 crore for January-March period (Q4) of financial year 2023-24.

see more..

Shriram Finance net jumps 57 pc to Rs 2,021 cr in Q4

26 Apr 2024 | 3:52 PM

New Delhi, April 26 (UNI) Shriram Finance on Friday reported 56.91% year-on-year jump in consolidated net profit at Rs 2,021.28 crore for the January-March period (Q4) of financial year 2023-24.

see more..
Maruti Suzuki gets show-cause notice from Legal Metrology dept

Maruti Suzuki gets show-cause notice from Legal Metrology dept

26 Apr 2024 | 2:39 PM

New Delhi, April 26 (UNI) The country's leading carmaker Maruti Suzuki India on Friday said that it has received a show-cause notice from the Legal Metrology office in Rishikesh, Uttarakhand.

see more..

Onkar Kanwar gets Lifetime Achievement Award

26 Apr 2024 | 2:08 PM

Kochi, April 26 (UNI) Chairman of Apollo Tyres Ltd, Onkar Kanwar, has been conferred with the Lifetime Achievement Award at the All India Management Association (AIMA)’s Managing India Awards ceremony.

see more..
image